Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Pfizer Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Primary Care 30,135 30,799 73,181 52,029 15,577
Specialty Care 16,652 14,988 13,851 15,194 14,280
Oncology 15,612 12,450 12,794 12,333 10,867
Global Biopharmaceuticals Business (Biopharma) 62,399 58,237 99,826 79,556 40,724
Pfizer Centreone 1,146 1,272 1,342 2,589 1,954
Pfizer Ignite 82 44 7
Revenues 63,627 59,553 101,175 82,145 42,678

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Pfizer Inc. revenues decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.